Researcher Profile

Researcher Profile

Jong Yun, PhD

Jong Yun, PhD

Associate Professor, Department of Pharmacology
Scientific Program:Next-Generation Therapies
jky1@psu.edu

Research Interests

Dr. Jong Yun's work focuses on the development of sphingosine kinase (SphK) inhibitors as anti-cancer therapeutic agents.

The Yun research group is currently pursuing three separate projects that are centered around the development of therapeutic agents that specifically target SphK.

The first project, target identification, combines biochemistry and cell and molecular biology techniques to determine the signaling mechanisms associated with the functional role of SphK in normal and cancerous cells.

The second project, target validation, is closely associated with the physiological and/or pathological functions of SphK. To validate SphK as a therapeutic target, the lab currently has ongoing studies in collaboration with other investigators including clinicians such as oncologists and pathologists.

The third project, proof-of-concept studies, centers around the development of novel disease-specific and effective therapeutic approaches by targeting SphK. In this regard, Dr. Yun's work has already identified and refined novel SphK inhibitors (SKIs) by screening libraries of synthetic compounds. Currently, the lab has several ongoing proof-of-concept studies in collaboration with other investigators who have expertise medicinal chemistry, computational chemistry and in vivo mouse model systems.

  • sphingosine kinase
  • Apoptosis
  • Therapeutics
  • Neoplasms
  • Ceramides
  • Growth
  • Proteins
  • Messenger RNA
  • Tumor Necrosis Factor-alpha
  • Cytokines
  • Protein Kinase C
  • Phosphotransferases

Recent Publications

2018

Bellon, A, Wegener, A, Lescallette, AR, Valente, M, Yang, SK, Gardette, R, Matricon, J, Mouaffak, F, Watts, P, Vimeux, L, Yun, JK, Kawasawa, YI, Clawson, GA, Blandin, E, Chaumette, B, Jay, TM, Krebs, MO, Feuillet, V & Hosmalin, A 2018, 'Transdifferentiation of Human Circulating Monocytes Into Neuronal-Like Cells in 20 Days and Without Reprograming', Frontiers in Molecular Neuroscience, vol. 11, 323. https://doi.org/10.3389/fnmol.2018.00323

2017

Hengst, J, Dick, TE, Sharma, A, Doi, K, Hegde, S, Tan, SF, Geffert, L, Fox, TE, Sharma, AK, Desai, D, Amin, S, Kester, M, Loughran, TP, Paulson, R, Claxton, D, Wang, H-G & Yun, J 2017, 'SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models', Cancer Translational Medicine, vol. 3, no. 4, pp. 109-121.

2016

Tan, SF, Liu, X, Fox, TE, Barth, BM, Sharma, A, Turner, SD, Awwad, A, Dewey, A, Doi, K, Spitzer, B, Shah, MV, Morad, SAF, Desai, D, Amin, S, Zhu, J, Liao, J, Yun, J, Kester, M, Claxton, DF, Wang, HG, Cabot, MC, Schuchman, EH, Levine, RL, Feith, DJ & Loughran, TP 2016, 'Acid ceramidase is upregulated in AML and represents a novel therapeutic target', Oncotarget, vol. 7, no. 50, pp. 83208-83222. https://doi.org/10.18632/oncotarget.13079
Young, MM, Takahashi, Y, Fox, TE, Yun, JK, Kester, M & Wang, HG 2016, 'Sphingosine Kinase 1 Cooperates with Autophagy to Maintain Endocytic Membrane Trafficking', Cell Reports, vol. 17, no. 6, pp. 1532-1545. https://doi.org/10.1016/j.celrep.2016.10.019

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)